Intercept Pharmaceuticals

$19.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.42 (-6.84%) Today
+$0.17 (+0.88%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ICPT and other stocks, options, and ETFs commission-free!

About ICPT

Intercept Pharmaceuticals, Inc. Common Stock, also called Intercept Pharmaceuticals, is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY. The listed name for ICPT is Intercept Pharmaceuticals, Inc. Common Stock.

CEO
Jerome B. Durso
Employees
583
Headquarters
New York, New York
Founded
2002
Market Cap
638.49M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.32M
High Today
$20.81
Low Today
$19.16
Open Price
$20.62
Volume
1.93M
52 Week High
$98.03
52 Week Low
$19.16

ICPT Earnings

-$2.99
-$2.48
-$1.98
-$1.47
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$1.47 per share
Actual
-$1.58 per share
Replay Earnings Call

You May Also Like

VHI
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure